Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

10.070
+0.5956.28%
Volume:158.14M
Turnover:1.58B
Market Cap:116.03B
PE:25.37
High:10.160
Open:9.350
Low:9.350
Close:9.475
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:2.50
T/O Rate:1.37%
Dividend:0.29
Dividend Rate:2.88%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.64
PE(LYR):25.37
PS:3.17

Loading ...

CSPC Pharma (01093) Surges Over 12% After Interim Profit Jumps Nearly 1.4-Fold

Stock News
·
Aug 20

CSPC Pharmaceutical Hits 6-Month High on Profit, Dividend Surge

Reuters
·
Aug 20

CSPC Pharmaceutical's Attributable Profit More Than Doubles in H1; Shares Jump 14%

MT Newswires Live
·
Aug 20

CSPC Pharma FY26 H1 Profit Attributable to Shareholders More than Doubled to RMB 6.09 Billion; Revenue Rises 40.1% to RMB 18.59 Billion

Reuters
·
Aug 20

CSPC Pharmaceutical Group H1 Net Income Attributable RMB 6,094.2 Million

THOMSON REUTERS
·
Aug 20

CSPC Pharmaceutical Group - Interim Dividend of HK18 Cents Per Share for 2026

THOMSON REUTERS
·
Aug 20

Movement Alert|CSPC PHARMA Rises 12.49% in Regular Trading, Interim Results Day Coupled with Multiple Positive Catalysts

Market Focus
·
Aug 20

CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Protein SYS6090 for Liver Cancer in China

Bulletin Express
·
Aug 19

CSPC Pharmaceutical Group Stock Sheds 1.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 19

Does FDA-Backed Mpox mRNA Trial and AstraZeneca Tie-Up Recast the Bull Case For CSPC (SEHK:1093)?

Simply Wall St.
·
Aug 19

CSPC Pharma Says NMPA Accepts NDA for KN026 and Hb1801 for Advanced Breast Cancer

Reuters
·
Aug 18

CSPC Pharma Unit's Breast Cancer Drug Application Granted Priority Review in China

MT Newswires Live
·
Aug 18

Alphamab Oncology Says China NMPA Accepts Anbenitamab NDA for First-Line HER2+ Advanced Breast Cancer

Reuters
·
Aug 18

CSPC Pharmaceutical - Kn026 and Hb1801 Combination Previously Granted Breakthrough Therapy Designation by Nmpa

THOMSON REUTERS
·
Aug 18

CSPC Pharmaceutical - Nda Indication: First-Line Treatment of Unresectable or Metastatic Her2-Positive Breast Cancer

THOMSON REUTERS
·
Aug 18

CSPC Innovation Posts RMB 1.26 Billion H1 Net Profit on RMB 3.24 Billion Revenue

Reuters
·
Aug 17

CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Billion Yuan

Reuters
·
Aug 17

Movement Alert|CSPC PHARMA Rises 3.22% in Regular Trading, Innovative Pharma Sector Strengthens as AstraZeneca Payments Confirmed

Market Focus
·
Aug 17

CSPC Pharmaceutical Group Stock Rallies 2.0% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 13

Earning Preview: CSPC PHARMA Q2 revenue expected to increase by 25.43%, institutional views are bullish

Earnings Agent
·
Aug 13